During the past decade, Fakultni Nemocnice Brno conducted 110 clinical trials. In the 10-year time frame, 110 clinical trials started and 76 clinical trials were completed, i.e. on average, 69.1% percent of trials that started reached the finish line to date. In the past 5 years, 43 clinical trials started and 40 clinical trials were completed. i.e. 93% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fakultni Nemocnice Brno" #1 sponsor was "Janssen Research & Development, LLC" with 16 trials, followed by "Bayer" with 9 trials sponsored, "Celgene" with 9 trials sponsored, "Hoffmann-La Roche" with 8 trials sponsored and "Pfizer" with 8 trials sponsored. Other sponsors include 118 different institutions and companies that sponsored additional 80 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fakultni Nemocnice Brno" #1 collaborator was "Eli Lilly and Company" with 6 trials as a collaborator, "Takeda Development Center Americas, Inc." with 3 trials as a collaborator, "AbbVie" with 2 trials as a collaborator, "Baxalta Innovations GmbH, now part of Shire" with 2 trials as a collaborator and "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 2 trials as a collaborator. Other collaborators include 27 different institutions and companies that were collaborators in the rest 36 trials.

According to Clinical.Site data, the most researched conditions in "Fakultni Nemocnice Brno" are "Multiple Myeloma" (18 trials), "Chronic Lymphocytic Leukemia" (9 trials), "Idiopathic Pulmonary Fibrosis" (5 trials), "Multiple Sclerosis" (5 trials) and "Small Lymphocytic Lymphoma" (5 trials). Many other conditions were trialed in "Fakultni Nemocnice Brno" in a lesser frequency.

Most popular intervention types in "Fakultni Nemocnice Brno" are "Drug" (146 trials), "Other" (23 trials), "Biological" (15 trials), "Device" (7 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (47 trials), "Dexamethasone" (19 trials), "Rituximab" (13 trials), "Bortezomib" (11 trials) and "Daratumumab" (11 trials). Other intervention names were less common.

The vast majority of trials in "Fakultni Nemocnice Brno" are 160 trials for "All" genders, 9 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Fakultni Nemocnice Brno". 1 are not yet recruiting, 36 are recruiting, 23 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 88 completed trials in Fakultni Nemocnice Brno, undefined suspended trials, and 23 terminated clinical trials to date.

Out of the total trials that were conducted in Fakultni Nemocnice Brno, 10 "Phase 1" clinical trials were conducted, 48 "Phase 2" clinical trials and 109 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 8 trials that are defined as “Not Applicable".

Fakultni Nemocnice Brno has several departments that took part in Clinical trials: "Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika" - 23 trials, "University Hospital Brno, Clinic of Internal Medicine - Hematology and Oncology" - 9 trials, "Fakultni nemocnice Brno Neurologicka klinika" - 7 trials, "Kardiologicka Ambulance" - 4 trials